IBDEI1E6 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,22514,0)
;;=R60.0^^76^970^6
;;^UTILITY(U,$J,358.3,22514,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22514,1,3,0)
;;=3^Edema,Localized
;;^UTILITY(U,$J,358.3,22514,1,4,0)
;;=4^R60.0
;;^UTILITY(U,$J,358.3,22514,2)
;;=^5019532
;;^UTILITY(U,$J,358.3,22515,0)
;;=L53.0^^76^970^14
;;^UTILITY(U,$J,358.3,22515,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22515,1,3,0)
;;=3^Erythema Toxic
;;^UTILITY(U,$J,358.3,22515,1,4,0)
;;=4^L53.0
;;^UTILITY(U,$J,358.3,22515,2)
;;=^5009207
;;^UTILITY(U,$J,358.3,22516,0)
;;=L53.1^^76^970^9
;;^UTILITY(U,$J,358.3,22516,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22516,1,3,0)
;;=3^Erythema Annulare Centrifugum
;;^UTILITY(U,$J,358.3,22516,1,4,0)
;;=4^L53.1
;;^UTILITY(U,$J,358.3,22516,2)
;;=^5009208
;;^UTILITY(U,$J,358.3,22517,0)
;;=L51.9^^76^970^12
;;^UTILITY(U,$J,358.3,22517,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22517,1,3,0)
;;=3^Erythema Multiforme,Unspec
;;^UTILITY(U,$J,358.3,22517,1,4,0)
;;=4^L51.9
;;^UTILITY(U,$J,358.3,22517,2)
;;=^336759
;;^UTILITY(U,$J,358.3,22518,0)
;;=L12.35^^76^970^8
;;^UTILITY(U,$J,358.3,22518,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22518,1,3,0)
;;=3^Epidermolysis Bullosa,Acquired
;;^UTILITY(U,$J,358.3,22518,1,4,0)
;;=4^L12.35
;;^UTILITY(U,$J,358.3,22518,2)
;;=^5009100
;;^UTILITY(U,$J,358.3,22519,0)
;;=L52.^^76^970^13
;;^UTILITY(U,$J,358.3,22519,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22519,1,3,0)
;;=3^Erythema Nodosum
;;^UTILITY(U,$J,358.3,22519,1,4,0)
;;=4^L52.
;;^UTILITY(U,$J,358.3,22519,2)
;;=^42065
;;^UTILITY(U,$J,358.3,22520,0)
;;=L49.0^^76^970^26
;;^UTILITY(U,$J,358.3,22520,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22520,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
;;^UTILITY(U,$J,358.3,22520,1,4,0)
;;=4^L49.0
;;^UTILITY(U,$J,358.3,22520,2)
;;=^5009190
;;^UTILITY(U,$J,358.3,22521,0)
;;=L49.1^^76^970^17
;;^UTILITY(U,$J,358.3,22521,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22521,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
;;^UTILITY(U,$J,358.3,22521,1,4,0)
;;=4^L49.1
;;^UTILITY(U,$J,358.3,22521,2)
;;=^5009191
;;^UTILITY(U,$J,358.3,22522,0)
;;=L49.2^^76^970^18
;;^UTILITY(U,$J,358.3,22522,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22522,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
;;^UTILITY(U,$J,358.3,22522,1,4,0)
;;=4^L49.2
;;^UTILITY(U,$J,358.3,22522,2)
;;=^5009192
;;^UTILITY(U,$J,358.3,22523,0)
;;=L49.3^^76^970^19
;;^UTILITY(U,$J,358.3,22523,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22523,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
;;^UTILITY(U,$J,358.3,22523,1,4,0)
;;=4^L49.3
;;^UTILITY(U,$J,358.3,22523,2)
;;=^5009193
;;^UTILITY(U,$J,358.3,22524,0)
;;=L49.4^^76^970^20
;;^UTILITY(U,$J,358.3,22524,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22524,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
;;^UTILITY(U,$J,358.3,22524,1,4,0)
;;=4^L49.4
;;^UTILITY(U,$J,358.3,22524,2)
;;=^5009194
;;^UTILITY(U,$J,358.3,22525,0)
;;=L49.5^^76^970^21
;;^UTILITY(U,$J,358.3,22525,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22525,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
;;^UTILITY(U,$J,358.3,22525,1,4,0)
;;=4^L49.5
;;^UTILITY(U,$J,358.3,22525,2)
;;=^5009195
;;^UTILITY(U,$J,358.3,22526,0)
;;=L49.6^^76^970^22
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1E6 3782 printed Sep 15, 2024@21:31:12 Page 2
IBDEI1E6 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,22514,0)
+2 ;;=R60.0^^76^970^6
+3 ;;^UTILITY(U,$J,358.3,22514,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,22514,1,3,0)
+6 ;;=3^Edema,Localized
+7 ;;^UTILITY(U,$J,358.3,22514,1,4,0)
+8 ;;=4^R60.0
+9 ;;^UTILITY(U,$J,358.3,22514,2)
+10 ;;=^5019532
+11 ;;^UTILITY(U,$J,358.3,22515,0)
+12 ;;=L53.0^^76^970^14
+13 ;;^UTILITY(U,$J,358.3,22515,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,22515,1,3,0)
+16 ;;=3^Erythema Toxic
+17 ;;^UTILITY(U,$J,358.3,22515,1,4,0)
+18 ;;=4^L53.0
+19 ;;^UTILITY(U,$J,358.3,22515,2)
+20 ;;=^5009207
+21 ;;^UTILITY(U,$J,358.3,22516,0)
+22 ;;=L53.1^^76^970^9
+23 ;;^UTILITY(U,$J,358.3,22516,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,22516,1,3,0)
+26 ;;=3^Erythema Annulare Centrifugum
+27 ;;^UTILITY(U,$J,358.3,22516,1,4,0)
+28 ;;=4^L53.1
+29 ;;^UTILITY(U,$J,358.3,22516,2)
+30 ;;=^5009208
+31 ;;^UTILITY(U,$J,358.3,22517,0)
+32 ;;=L51.9^^76^970^12
+33 ;;^UTILITY(U,$J,358.3,22517,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,22517,1,3,0)
+36 ;;=3^Erythema Multiforme,Unspec
+37 ;;^UTILITY(U,$J,358.3,22517,1,4,0)
+38 ;;=4^L51.9
+39 ;;^UTILITY(U,$J,358.3,22517,2)
+40 ;;=^336759
+41 ;;^UTILITY(U,$J,358.3,22518,0)
+42 ;;=L12.35^^76^970^8
+43 ;;^UTILITY(U,$J,358.3,22518,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,22518,1,3,0)
+46 ;;=3^Epidermolysis Bullosa,Acquired
+47 ;;^UTILITY(U,$J,358.3,22518,1,4,0)
+48 ;;=4^L12.35
+49 ;;^UTILITY(U,$J,358.3,22518,2)
+50 ;;=^5009100
+51 ;;^UTILITY(U,$J,358.3,22519,0)
+52 ;;=L52.^^76^970^13
+53 ;;^UTILITY(U,$J,358.3,22519,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,22519,1,3,0)
+56 ;;=3^Erythema Nodosum
+57 ;;^UTILITY(U,$J,358.3,22519,1,4,0)
+58 ;;=4^L52.
+59 ;;^UTILITY(U,$J,358.3,22519,2)
+60 ;;=^42065
+61 ;;^UTILITY(U,$J,358.3,22520,0)
+62 ;;=L49.0^^76^970^26
+63 ;;^UTILITY(U,$J,358.3,22520,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,22520,1,3,0)
+66 ;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
+67 ;;^UTILITY(U,$J,358.3,22520,1,4,0)
+68 ;;=4^L49.0
+69 ;;^UTILITY(U,$J,358.3,22520,2)
+70 ;;=^5009190
+71 ;;^UTILITY(U,$J,358.3,22521,0)
+72 ;;=L49.1^^76^970^17
+73 ;;^UTILITY(U,$J,358.3,22521,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,22521,1,3,0)
+76 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
+77 ;;^UTILITY(U,$J,358.3,22521,1,4,0)
+78 ;;=4^L49.1
+79 ;;^UTILITY(U,$J,358.3,22521,2)
+80 ;;=^5009191
+81 ;;^UTILITY(U,$J,358.3,22522,0)
+82 ;;=L49.2^^76^970^18
+83 ;;^UTILITY(U,$J,358.3,22522,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,22522,1,3,0)
+86 ;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
+87 ;;^UTILITY(U,$J,358.3,22522,1,4,0)
+88 ;;=4^L49.2
+89 ;;^UTILITY(U,$J,358.3,22522,2)
+90 ;;=^5009192
+91 ;;^UTILITY(U,$J,358.3,22523,0)
+92 ;;=L49.3^^76^970^19
+93 ;;^UTILITY(U,$J,358.3,22523,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,22523,1,3,0)
+96 ;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
+97 ;;^UTILITY(U,$J,358.3,22523,1,4,0)
+98 ;;=4^L49.3
+99 ;;^UTILITY(U,$J,358.3,22523,2)
+100 ;;=^5009193
+101 ;;^UTILITY(U,$J,358.3,22524,0)
+102 ;;=L49.4^^76^970^20
+103 ;;^UTILITY(U,$J,358.3,22524,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,22524,1,3,0)
+106 ;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
+107 ;;^UTILITY(U,$J,358.3,22524,1,4,0)
+108 ;;=4^L49.4
+109 ;;^UTILITY(U,$J,358.3,22524,2)
+110 ;;=^5009194
+111 ;;^UTILITY(U,$J,358.3,22525,0)
+112 ;;=L49.5^^76^970^21
+113 ;;^UTILITY(U,$J,358.3,22525,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,22525,1,3,0)
+116 ;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
+117 ;;^UTILITY(U,$J,358.3,22525,1,4,0)
+118 ;;=4^L49.5
+119 ;;^UTILITY(U,$J,358.3,22525,2)
+120 ;;=^5009195
+121 ;;^UTILITY(U,$J,358.3,22526,0)
+122 ;;=L49.6^^76^970^22
